Century Therapeutics (IPSC) CEO has 55,397 shares withheld for RSU taxes

Rhea-AI Filing Summary

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a routine tax-related share disposition. The company withheld 55,397 shares of Common Stock at $2.73 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Pfeiffenberger directly holds 3,710,958 shares of Century Therapeutics common stock. This event reflects compensation-related tax settlement rather than an open-market stock sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		F(1)		55,397	D	$2.73	3,710,958	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Douglas Carr, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Century Therapeutics (IPSC) report for Brent Pfeiffenberger?

Century Therapeutics reported that President and CEO Brent Pfeiffenberger had 55,397 common shares withheld to cover tax obligations from restricted stock unit vesting. This is a compensation-related tax settlement, not an open-market purchase or sale of stock.

Was the IPSC CEO’s Form 4 transaction an open-market sale of shares?

No, the IPSC CEO’s transaction was not an open-market sale. The 55,397 shares were withheld by the company to satisfy tax withholding obligations tied to vesting restricted stock units, a common non-discretionary mechanism for equity compensation taxes.

How many Century Therapeutics (IPSC) shares were involved in the CEO’s tax withholding?

The transaction involved 55,397 shares of Century Therapeutics common stock, valued at $2.73 per share for tax purposes. These shares were retained by the issuer to satisfy the CEO’s tax obligations from restricted stock unit vesting, rather than being sold in the market.

How many Century Therapeutics (IPSC) shares does the CEO hold after this Form 4 transaction?

Following the tax-withholding transaction, Brent Pfeiffenberger directly holds 3,710,958 shares of Century Therapeutics common stock. This figure reflects his remaining direct ownership after 55,397 shares were withheld by the issuer to cover tax obligations from restricted stock unit vesting.

What does the F code mean in the Century Therapeutics (IPSC) Form 4 filing?

The F transaction code indicates shares were used to pay taxes or an exercise price. In this case, 55,397 Century Therapeutics shares were withheld by the issuer to satisfy Brent Pfeiffenberger’s tax obligations from vesting restricted stock units, not sold on the open market.